Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11:45	Karolinska Development’s Chairman of the Board resigns at his own request (GlobeNewswire)
10.12.24	Karolinska Development divests 4,6 million shares in portfolio company OssDsign (GlobeNewswire)
09.12.24	Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia (GlobeNewswire)
02.12.24	Karolinska Development implements organizational changes for more efficient portfolio management (GlobeNewswire)
19.11.24	Karolinska Development's portfolio company Modus Therapeutics secures bridge financing (GlobeNewswire)
18.11.24	Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study (GlobeNewswire)
15.11.24	Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO (GlobeNewswire)
15.11.24	Interim Report - January-September 2024 (GlobeNewswire)
13.11.24	Karolinska Development’s Extraordinary General Meeting 2024 (GlobeNewswire)
05.11.24	Karolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment (GlobeNewswire)
21.10.24	Karolinska Development’s portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine (GlobeNewswire)
17.10.24	Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024 (GlobeNewswire)
15.10.24	Notice of Extraordinary General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
23.09.24	Karolinska Development divests its holding in the Danish dermatology company Henlez (GlobeNewswire)
17.09.24	Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01 (GlobeNewswire)
17.09.24	Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease (GlobeNewswire)
30.08.24	Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 (GlobeNewswire)
30.08.24	Interim Report - January-June 2024 (GlobeNewswire)
16.07.24	Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator (GlobeNewswire)
10.07.24	Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone (GlobeNewswire)
12.06.24	Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection (GlobeNewswire)
28.05.24	Karolinska Development invests in BOOST Pharma, expanding its portfolio (GlobeNewswire)
16.05.24	Karolinska Development’s Annual General Meeting 2024 (GlobeNewswire)
08.05.24	Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC (GlobeNewswire)
26.04.24	Interim Report - January-March 2024 (GlobeNewswire)
16.04.24	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
22.03.24	Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC (GlobeNewswire)
22.03.24	Karolinska Development Annual Report 2023 published (GlobeNewswire)
14.03.24	Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million (GlobeNewswire)
14.03.24	Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units (GlobeNewswire)
06.03.24	Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD (GlobeNewswire)
16.02.24	Year-end Report - January-December 2023 (GlobeNewswire)
17.01.24	Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round (GlobeNewswire)
09.01.24	Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product (GlobeNewswire)
06.12.23	Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates (GlobeNewswire)
04.12.23	Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration (GlobeNewswire)
28.11.23	Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis (GlobeNewswire)
17.11.23	Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone (GlobeNewswire)
17.11.23	Interim Report - January-September 2023 (GlobeNewswire)
08.11.23	Karolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin (GlobeNewswire)
02.10.23	Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047 (GlobeNewswire)
28.09.23	Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047 (GlobeNewswire)
27.09.23	Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company (GlobeNewswire)
19.09.23	Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten